Disease monitoring programs of rare genetic diseases: transparent data sharing between academic and commercial stakeholders

Orphanet Journal of Rare Diseases

Hanns Lochmüller¹  Emil Kakkis²  Antonio Nino Ramirez² 

[1] Children’s Hospital of Eastern Ontario Research Institute, Ottawa, Canada;Division of Neurology, Department of Medicine, The Ottawa Hospital, Ottawa, Canada;Brain and Mind Research Institute, University of Ottawa, Ottawa, Canada;Ultragenyx Pharmaceutical Inc., Novato, CA, USA;

关键词: Orphan drugs;    Registry;    Registries;    Data sharing;    Disease monitoring program;    DMP;    GNE myopathy;    GNE myopathy disease monitoring program;    GNEM-DMP;   

DOI  :  10.1186/s13023-021-01687-7

来源: Springer

【 摘 要 】

It has recently been suggested that registries for rare neuromuscular diseases should be formed and governed exclusively by physicians and patients in an effort to limit conflicts of interest. Enacting such an approach would not only be challenging logistically and financially, but it would also exclude the involvement of sponsors, who are an integral component of drug development within the current compliance framework. Therefore, as an alternative to traditional registries, we propose the use of a better collaborative model for post-marketing follow-up that includes all stakeholders. We developed the concept of Disease Monitoring Programs (DMPs), which are designed to monitor disease manifestations over a 10-year period whether on a sponsored drug or not, and ensure consistent collection, ownership sharing and governance of data.

【 授权许可】

CC BY